This month, Neupulse has the honour of announcing that our Chief Scientific Officer, Professor Stephen Jackson, recognised as one of the foremost experts in the field of Tourette Syndrome, has been invited to discuss our transformative research at several esteemed events as well as shedding light on the latest advancements in understanding Tourette Syndrome.
These invitations underscore the international recognition of Professor Jackson's significant contributions to the field and Neupulse's role in pioneering research that promises to enhance the current treatment of Tourette Syndrome.
Company number: 13198315
Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham
England
NG7 2TU
Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd